| Name | Title | Contact Details |
|---|
Crossroads Automotive Group Inc. is a privately-held automotive dealership group based in Sanford, North Carolina, founded in 1996. The company specializes in new and used vehicle sales, service, and collision repair, operating multiple locations across North Carolina and Virginia. With a workforce of approximately 1,345 employees, Crossroads Automotive Group generates annual revenue of about $232 million. The company is committed to a customer-centric vehicle buying experience, guided by Christian principles. It emphasizes hiring skilled staff, maintaining large inventories, and providing compassionate service. Crossroads Automotive Group has expanded through acquisitions, including brands like Ford, Lincoln, INFINITI, Chrysler, Dodge, Jeep, and Ram. In addition to vehicle sales, the company offers automotive service, collision repair, maintenance, and financing options. It operates under various names, including Crossroads Ford and Crossroads Auto Group, and has established a strong presence in the automotive market.
bPrescient is a full-service scientific and technology consultancy dedicated to meeting the information management, data science, and analytics needs of the biotech, pharmaceutical, diagnostics, and healthcare industries. With bPrescients industry-leading ecosystem of experts, we offer a unique combination of both depth and breadth of knowledge to provide comprehensive support across: • The entire drug discovery process (from early-stage research to commercialization) • The diagnostics R&D lifecycle • The innovation challenges of the provider / payer domains At bPrescient, we pride ourselves on solving highly complex and difficult challenges. Our clients trust us to provide effective solutions to the problems they face today while anticipating, and helping them avoid, future challenges that catch many organizations unaware. There are three classes of problems we solve for clients: • Strategic & Advisory • Analytical & Scientific • Systems Integration, Design & Build Central to our model is the building of long-term relationships with our clients, which is why we go above and beyond to deliver exceptional results and value to those who need our assistance. Whether you are facing specific challenges today or are thinking about longer-term strategic goals, bPrescient is here to provide the support you need to succeed in the highly competitive biotech, pharmaceutical, diagnostics, and healthcare industries.
Syensqo is a leading science company whose ground-breaking technologies revolutionize the way we live. Our purpose is to advance human progress while cultivating a future for our planet that is not only safer and cleaner, but also inherently more sustainable, driven by the principles of circular economy. Our disruptive, market-leading solutions address fundamental megatrends. We play a key role in the future of clean mobility and bring about breakthroughs in biotechnology, natural ingredients, and circular solutions, contributing to sustainable, high-performance products for homes, food and consumer goods, planes, cars, smart devices, and healthcare applications. Inspired by the scientific councils, which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates in 30 countries.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The BIG3 is the premier league for 3v3 hoops. Featuring many of the worlds most popular and accomplished athletes.